RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
The Company Received Approval in Multiple European Countries to Initiate this Key Study Necessary for Commercial Product Approval
LOWELL, Mass.–(BUSINESS WIRE)–RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial.
